We have collected information about Formulation And Delivery Issues For Monoclonal Antibody Therapeutics for you. Follow the links to find out details on Formulation And Delivery Issues For Monoclonal Antibody Therapeutics.
https://www.sciencedirect.com/science/article/pii/S0169409X06000895
Due to their proteinacous nature, antibodies present generic formulation issues that are similar for most protein therapeutics [11]. Proteins, in general, can be degraded under conditions when they are exposed to heat, freezing, light, pH extremes, agitation, sheer-stress, some metals and organic solvents.Author: Ann L. Daugherty, Randall J. Mrsny
https://www.ncbi.nlm.nih.gov/pubmed/16839640
Aug 07, 2006 · Formulation and delivery issues for monoclonal antibody therapeutics. Daugherty AL(1), Mrsny RJ. Author information: (1)Genentech, Inc., 1 DNA Way South San Francisco, CA 94080, USA. [email protected] Antibodies can have exquisite specificity of target recognition and thus generate highly selective outcomes following their systemic administration.Author: Ann L. Daugherty, Randall J. Mrsny
https://rd.springer.com/chapter/10.1007/978-0-387-76643-0_8
Oct 10, 2009 · Kawade Y (1985) Neutralization of activity of effector protein by monoclonal antibody: formulation of antibody dose-dependence of neutralization for an equilibrium system of antibody, effector, and its cellular receptor.Author: Ann L. Daugherty, Randall J. Mrsny
https://www.sciencedirect.com/science/article/abs/pii/S0169409X06000895
Additionally, genetic engineering of antibodies has provided a stable of antibody-like proteins that can be easier to prepare. Together, these advances have made antibody-based therapies one of the most commonly pursued pharmaceuticals in biotechnology pipelines.Author: Ann L. Daugherty, Randall J. Mrsny
https://www.researchgate.net/publication/290271044_Formulation_and_Delivery_Issues_for_Monoclonal_Antibody_Therapeutics
Therapeutic and diagnostic antibodies have become the fastest growing area of biopharmaceutical applications. There are now 18 monoclonal antibodies on the market and over 100 in clinical trials, which highlights the significance of these therapeutics and the advances made in antibody engineering.
https://researchportal.bath.ac.uk/en/publications/formulation-and-delivery-issues-for-monoclonal-antibody-therapeut
Formulation and delivery issues for monoclonal antibody therapeutics. Advanced Drug Delivery Reviews, 58(5-6), ... Formulation and delivery issues for monoclonal antibody therapeutics. ... Formulation and delivery issues for monoclonal antibody therapeutics. AU - Daugherty, A L. AU - Mrsny, R J. PY - 2006.Author: Ann L. Daugherty, Randall J. Mrsny
https://www.infona.pl/resource/bwmeta1.element.elsevier-ad831120-556d-306d-a7db-1b7289154691
With this success, however, has come a series of technical challenges in the formulation of antibody-based materials to maintain sufficient stability in a variety of configurations and sometimes at particularly high concentrations. This review focuses on issues related to identifying and verifying stable antibody-based formulations.
https://www.researchgate.net/publication/6945328_Daugherty_AL_Mrsny_RJ_Formulation_and_delivery_issues_for_monoclonal_antibody_therapeutics_Adv_Drug_Deliv_Rev_58_686-706
Formulation and delivery of proteins and peptides, such as monoclonal antibodies, aptamers, recombinant proteins and peptides to ocular tissues poses significant challenges owing to their large...
https://www.tandfonline.com/doi/10.4161/19420862.2014.975658
(2014). Resolving self-association of a therapeutic antibody by formulation optimization and molecular approaches. mAbs: Vol. 6, No. 6, pp. 1533-1539.
Searching for Formulation And Delivery Issues For Monoclonal Antibody Therapeutics?
You can just click the links above. The data is collected for you.
